Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

206.89 +0.55 (+0.27%)
Streaming Delayed Price Updated: 4:15 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
25 26 Next >
RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Thomson Reuters: Here's What You Need To Know
 
Via Benzinga
Preview: RBC Bearings's Earnings
 
Via Benzinga
RBC Capital Maintains Outperform Rating for Ensign Group: Here's What You Need To Know
 
Via Benzinga
Uber, Lyft Can Hitch A Ride Higher If Q4 Earnings Beat Wall Street Estimates
Uber reports on Wednesday, while Lyft Q4s are on Feb. 13. RBC has a sector perform rating on Lyft and an outperform rating on Uber. 
Via Benzinga
Topics Earnings
Capstone Copper Announces Multimillion-Dollar Financing To Support Its Chilean Expansion
Capstone Copper Corp. and Orion Mine Finance arranged a CA$375 million bought deal with RBC Capital Markets, expected to close on Feb. 8, 2024. 
Via Benzinga
The Weird And Depressing Debate Over AS/AD
I didn’t know that hardcore RBC types had a view on this question, but today I’m more interested in Tyler’s comment on aggregate demand. 
Via Talk Markets
The Analyst Landscape: 5 Takes On RBC Bearings
 
Via Benzinga
RBC Capital Maintains Outperform Rating for Reinsurance Gr: Here's What You Need To Know
 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know
 
Via Benzinga
RBC Capital Maintains Outperform Rating for Thermo Fisher Scientific: Here's What You Need To Know
 
Via Benzinga
What's In Store For Clorox This Earnings Season? Analyst Sees Issues With Trash Bags, Cat Litter & More
Clorox faces challenges in key product categories like trash bags and cat litter, hindering recovery from the 2023 cyber-attack, according to RBC analyst Nik Modi. 
Via Benzinga
'We Stay The Course On Meta And Amazon': Analysts Preview Tech Earnings
RBC is looking for acceleration in Amazon's AWS cloud offering and expects increasing adoption of Advantage+ to be a key driver of Meta. 
Via Benzinga
Foresight to Participate in A.G.P’s Virtual Technology Conference
--News Direct-- 
Via News Direct
Topics Regulatory Compliance
Foresight to Participate in A.G.P’s Virtual Technology Conference
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“FRSX” or the “Company”), an innovator in automotive vision systems, today announced that management will participate in the Alliance Global... 
Via TheNewswire.com
Topics Regulatory Compliance
RBC Capital Maintains Outperform Rating for Popular: Here's What You Need To Know
 
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
RBC Capital Maintains Outperform Rating for ServiceNow: Here's What You Need To Know
 
Via Benzinga
Post Event Report - The Future of Insurance Canada 2023
London, United Kingdom--(Newsfile Corp. - January 25, 2024) - In 2023 business was anything but as usual. Spiraling costs, accelerated... 
Via Newsfile
RBC Capital Maintains Sector Perform Rating for Procter & Gamble: Here's What You Need To Know
 
Via Benzinga
Rio Tinto and BHP stock: Can mining giants unearth profit growth?
Analysts and mining company CEOs are upbeat about the global market for copper, iron ore and other metals, despite mining stocks' recent price declines. 
Via MarketBeat
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
RBC Capital Upgrades Taylor Morrison Home: Here's What You Need To Know
 
Via Benzinga
RBC Capital Maintains Outperform Rating for Realty Income: Here's What You Need To Know
 
Via Benzinga
BlackBerry Analyst Cites Concerns On Visibility, Financing Despite Q3 Earnings Beat: Here Are The Details
RBC Capital Markets analyst Paul Treiber maintained the Sector Perform rating on BlackBerry Ltd (NYSE: BB) and cut the price target to $4 from $4.50 despite the third-quarter 
Via Benzinga
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
RBC Capital Maintains Outperform Rating for FirstService: Here's What You Need To Know
 
Via Benzinga
Equinor Downgraded: Analyst Highlights Faster Balance Sheet Re-leveraging And Modest 2024 Distributions
RBC Capital Markets analyst Biraj Borkhataria downgraded Equinor ASA (NYSE: EQNR) to Sector Perform from Outperform and cut the price target  
Via Benzinga
RBC Capital Maintains Outperform Rating for Louisiana-Pacific: Here's What You Need To Know
 
Via Benzinga
RBC Capital Maintains Outperform Rating for Huntington Bancshares: Here's What You Need To Know
 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.